Trials / Unknown
UnknownNCT03825848
The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
The Influence of Shunting Left/Right Portal Vein Branch on Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: a Multicenter Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Through a multicenter randomized controlled trial of TIPS to prevent post-hepatitis B cirrhosis of esophagogastric varices, the incidence of hepatic encephalopathy, the rate of stent patency, the incidence of rebleeding and survival in the left and right branches of the portal vein were compared.
Detailed description
The most common cause of cirrhosis in China is hepatitis B virus infection; post-hepatitis B cirrhosis with gastroesophageal variceal hemorrhage is common in clinical practice; recent studies \[14\] found that implantation of 8 mm diameter is compared with the use of 10 mm diameter stents. The membrane stent significantly reduced the incidence of HE after TIPS without affecting the shunt effect. To further evaluate the effect of "left/right branch of shunt portal" on hepatic encephalopathy after TIPS, we intend to conduct the following studies: for individual etiology (post-hepatitis B cirrhosis), the only indication (to prevent recurrent rupture of gastroesophageal varices) ), implanted 8mm diameter Viatorr stent, unified HE evaluation criteria, and stratified multi-center randomized clinical trial study with Child classification, hope to guide TIPS in line with China's national conditions through the high-level evidence-based medical evidence obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | trans jugular intrahepatic portal systemic shunt | Shunting left or right PV branch in the TIPS procedure |
Timeline
- Start date
- 2019-06-20
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2019-01-31
- Last updated
- 2019-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03825848. Inclusion in this directory is not an endorsement.